No abstract

These findings suggest that high-glucose conditions enhance the susceptibility of MCs to the cytotoxic effects of both contrast media; the enhanced susceptibility was in part attributable to oxidative stress caused by high-glucose conditions; diatrizoate exerted the cytotoxic effects by means of oxidative stress; and iohexol appeared to exert its cytotoxicity in a manner different from diatrizoate.

(2017) A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the doubleblind period in three randomized, placebo-controlled studies, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 18:sup1, 71-79, DOI: 10.1080/21678421.2017 Abstract Background: There continues to be a need for new therapies to treat ALS. Objective: Provide an overview of safety for edaravone in ALS patients during the first six cycles of treatment. Methods: Analysis was based on three randomised, placebo-controlled clinical trials. Endpoints included treatment-emergent adverse events (TEAEs), including AEs leading to discontinuation, serious adverse events (SAEs), and deaths. Results: The analysis included a total of 368 patients (184 in the edaravone group and placebo group, respectively). Of those, 94.6% of the edaravone group and 90.2% of placebo group completed six cycles of therapy. Baseline characteristics were comparable between the two groups. TEAE incidence in the edaravone group and placebo group was 87.5% and 87.0%, respectively. TEAEs ocurring at 2% incidence in the edaravone group compared to placebo were contusion (14.7% vs. 8.7%), gait disturbance (12.5% vs. 9.2%), headache (8.2% vs. 5.4%), eczema (6.5% vs. 2.2%), dermatitis contact (6.0% vs. 3.3%), respiratory disorder (4.3% vs. 1.1%), and glucose urine present (3.8% vs. 1.6%). There was no imbalance in TEAEs leading to discontinuation (2.2% [edaravone], and 5.4% [placebo]). SAE incidence was 17.4% in the edaravone group and 22.3% in placebo group. Treatment-emergent deaths occurred in 2.2% in the edaravone group and 1.1% in placebo group, all respiratory in nature and attributed to worsening ALS. Conclusion: Data collected from three double-blind assessments found that while some TEAEs were more common in the edaravone group compared to placebo, the overall incidences of SAEs, deaths, and discontinuations due to AEs were similar or less for edaravone compared to placebo.

These findings suggest that iobitridol has significantly less toxic effects on the kidney compared with iohexol under the condition of our experiment.

Rabbit anti-glomerular basement membrane serum (AGBM) or normal rabbit serum (NRS) were given intravenously (2 ml/kg body weight) to 8 male beagle dogs. Light and transmission electron microscopy and immunofluorescence were performed on the kidneys on day 7 postinjection. Alterations of anionic sites (ASs) of glomerular basement membrane (GBM) in peripheral, proximal, and paramesangial portions were studied quantitatively by electron microscopy using polyethyleneimine (PEI; molecular weight = 1,800) as a cationic probe. Severe or mild proteinuria developed on day 1 and continued until day 6 postinjection. On day 7 after AGBM injection, the number of PEI granules per 1,000 nm length of the lamina rara externa of GBM in all portions was significantly less than that in NRS-treated dogs (10.48 +/- 1.78 versus 14.19 +/- 2.35 granules per 1,000 nm of GBM in peripheral portion, 10.81 +/- 1.91 versus 14.97 +/- 1.35 granules per 1,000 nm of GBM in proximal portion, 8.44 +/- 1.76 vs 13.43 +/- 2.10 granules per 1,000 nm of GBM in paramesangial portion; p < 0.001). These results indicate that a reduction glomerular AS occurs in AGBM-treated dogs in association with severe or mild proteinuria and alterations in glomerular ASs might play an important role in the pathogenesis of proteinuria in the canine anti-GBM nephritis in addition to morphological changes.